The earnings call reflects a strong positive sentiment, with significant revenue growth, strategic partnerships, and international expansion contributing to the optimism. While there are some challenges related to FDA remediation and potential tariff impacts, the overall outlook remains robust due to effective execution and innovative initiatives.

Company Guidance

During the iRhythm Technologies Q2 2025 earnings call, the company provided updated guidance for the year, reflecting strong performance and growth prospects. The company reported $186.7 million in revenue for the second quarter, marking a 26.1% year-over-year increase, driven by robust performance in their core business and innovative channel partnerships. Adjusted EBITDA margin for the quarter was 8.4%, a 500 basis point improvement from the previous year. For the full year 2025, iRhythm raised its revenue guidance to a range of $720 million to $730 million and adjusted EBITDA margin to 8% to 8.5%. Notably, new store growth contributed significantly to volume growth, accounting for approximately 68% of the year-over-year increase. Guidance considerations also included the expectation of slightly higher CMS rates in 2026 and ongoing investments in innovation and operational efficiencies. The company plans to file a 510(k) for its next-generation Zio MCT product this quarter, underscoring its commitment to maintaining market leadership and expanding its product offerings.

Strong Revenue Growth

iRhythm reported $186.7 million in revenue for Q2 2025, representing more than 26% year-over-year growth. This growth was driven by the core long-term continuous monitoring business, innovative channel partners, and the Zio AT product line.

Expansion in International Markets

iRhythm saw continued strong demand in the UK, uptake in four additional European countries, and a broad commercial launch in Japan, demonstrating the global potential of their platform.

Increase in New Account Openings

The company achieved record new account openings in long-term continuous monitoring, driven by innovative channel partnerships and the adoption of both Zio monitor and Zio AT by recently launched IDN customers.

Partnership with Lucem Health

iRhythm announced a partnership with Lucem Health to accelerate early detection of undiagnosed arrhythmias using predictive AI, aiming to shift from reactive care to proactive preventative care.

Improved Financial Metrics

The company expanded adjusted EBITDA margins by 500 basis points since Q2 of the previous year, while investing in growth initiatives, demonstrating sustainable operating leverage.

Irhythm Technologies (IRTC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IRTC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.33 / -	-1.48	―	―	―
Jul 31, 2025	2025 (Q2)	-0.49 / -0.44	-0.65	32.31% (+0.21)
May 01, 2025	2025 (Q1)	-0.96 / -0.97	-1.47	34.01% (+0.50)
Feb 20, 2025	2024 (Q4)	-0.33 / -0.04	-1.26	96.83% (+1.22)
Oct 30, 2024	2024 (Q3)	-0.80 / -1.48	-0.89	-66.29% (-0.59)
Aug 01, 2024	2024 (Q2)	-0.89 / -0.65	-0.61	-6.56% (-0.04)
May 02, 2024	2024 (Q1)	-0.97 / -1.47	-1.29	-13.95% (-0.18)
Feb 22, 2024	2023 (Q4)	-0.57 / -1.26	-0.67	-88.06% (-0.59)
Nov 02, 2023	2023 (Q3)	-0.64 / -0.89	-0.71	-25.35% (-0.18)
Aug 03, 2023	2023 (Q2)	-0.76 / -0.61	-0.8	23.75% (+0.19)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IRTC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$140.18	$164.97	+17.68%
May 01, 2025	$108.59	$131.12	+20.75%
Feb 20, 2025	$112.67	$119.44	+6.01%
Oct 30, 2024	$75.77	$72.44	-4.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Irhythm Technologies (IRTC) report earnings?

Irhythm Technologies (IRTC) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Irhythm Technologies (IRTC) earnings time?

Irhythm Technologies (IRTC) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IRTC EPS forecast?

IRTC EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing